E. M. Messing, J. Manola, J. Yao, M. Kiernan, D. Crawford, G. Wilding, P. A. di’SantAgnese and D. Trump, “Eastern Cooperative Oncology Group Study EST Immediate versus Deferred Androgen Deprivation Treatment in Patients with Node-Positive Prostate Cancer after Radical Prostatectomy and Pelvic Lymphadenectomy,” The Lancet Oncology, Vol. 7, No. 6, 2006, pp. 472-479. doi:10.1016/S1470-2045(06)70700-8

has been cited by the following article:

• TITLE: Gene Expression Profile, Androgen Independence and Prostate Cancer

  AUTHORS: Maxwell Omabe, Joel C. Onyeanusi, Nworie Amos, Martin Ezeani, Simon Imakwu Okekpa

  KEYWORDS: Prostate Cancer; Androgen Ablation; Gene Expression; Microarrays

  JOURNAL NAME: Journal of Cancer Therapy, Vol.3 No.5, October 18, 2012

  ABSTRACT: It is now generally accepted that the burden of disease due to prostate cancer has tremendously increased globally. Current data indicates that prostate cancer is the most common form of cancer in men in the United State of America, and the second leading cause of death due to cancer in men. Progression to androgen independence and subsequent therapeutic resistance and death is a common fate of patients with prostate cancer. This review highlights the gene expression profile of androgen independent prostate cancer and the possible mechanisms that results in transformation to such treatment resistant state.